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Abstract
Background: Bladder cancer is the ninth most commonly diagnosed malignancy worldwide. The trend of bladder cancer incidence
and mortality is rising in Iran. This study was aimed to evaluate the survival rate of patients with bladder cancer in Yazd province,
Iran.
Methods: In this retrospective cohort study, data were collected from 340 patients suffering from bladder cancer referred to Shahid
Rahnemon and Shohada-Kargar Hospitals in Yazd province, Iran between April, 2001 and March, 2012. Variables included age, gen-
der, stage of cancer, place of residence and type of treatment. The Kaplan-Meier and Cox regression analyses were used to evaluate
the relationship between each variable and survival time. A P value less than 0.05 was considered significant.
Results: The mean age of total patients was 65.8± 13.6 years, and their mean survival time was 68.55± 6.05 months. Cumulative
survival rates at the end of 1, 3, and 5 years in bladder cancer patients were 91%, 58%, and 51.4%, respectively. A statistically significant
association was found between age (P = 0.005), stage of disease (P = 0.0003), type of treatment (P = 0.0003) and survival time of
patients. Data showed no significant correlation between age, gender, place of residence and patients’ survival.
Conclusions: The survival of patients suffering from bladder cancer in this study was less than other reports. Patients’age and
cancer stage were the effective factors in survival time. Continuous screening of older people for cancer diagnosis in early stages is
seemed to improve survival in patients.
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1. Background
Bladder cancer is a common cancer of urinary tract
.The available statistics for bladder cancer show that this
malignancy is the ninth leading cause of cancer in the
world (1). The number of bladder cancer deaths has in-
creased from 114,000 in 1990 to 170,000 in 2010 (2). In 2012,
430,000 new bladder cancer cases and 165,000 deaths oc-
curred worldwide. About 60% of cases were diagnosed in
more developed countries. The highest incidence of this
cancer was in Northern America and Europe while the low-
est incidence was in Asia and Latin America (3). Bladder
cancer is the fourth most common cancer in Iranian men
(4). Based on the available data, bladder cancer is the sec-
ond, the third and the fifth common cancer in Markazi,
Hamedan and Fars provinces of Iran, respectively (4, 5).
Smoking is a serious risk factor for bladder cancer.
Smoking causes about 50% of all bladder cancers in
women and men (6). Other risk factors include age, race,
gender, chronic bladder infections, radiation exposure,
bladder birth defects and genetic history (5). Bladder can-
cer mainly occurs in the population older than 65 years
old. This cancer is about 3 - 4 times more prevalent in men
than women (4, 7). Several studies were conducted to esti-
mate the survival rate of bladder cancer in the world (4).
According to the most recent data, the general 5-year rela-
tive survival rate for patients with bladder cancer (includ-
ing all stages) is 77%, and the 10-year relative survival rate is
about 70%. Survival rate of bladder cancer is dependent on
metastasis to other organs, stage, grade and size of tumor
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(7). For patients with non-muscle invasive bladder cancer,
the 5-year survival rate is 96%, while for patients with inva-
sive tumor, the 5-year survival rate is 70%. If the bladder tu-
mor spreads to the surrounding tissues, lymph nodes or
organs, the 5-year survival rate is 34% (3).
Mortality and bladder cancer survival rates are known
to vary considerably among countries in terms of public
health care system, access to diagnosis and treatment fa-
cilities, and effective treatment protocols. Cancer survival
statistics can be useful for determining prognosis and eval-
uating treatment options. Therefore, knowing about can-
cer survival rates in any country and its provinces/states is
necessary (3). Although bladder cancer incidence has in-
creased in the last 15 years in Iran, the survival rate of Ira-
nian patients is not clear in all regions of the country (4).
Published data on survival of patients with bladder cancer
in Iran are really little. The present study aimed to deter-
mine, for the first time, the survival rate of patients with
bladder cancer in Yazd province.
2. Methods
This retrospective cohort study was conducted on 340
patients with bladder cancer referred to Shahid Rahnemon
and Shohada-Kargar Hospitals in Yazd, Iran between April,
2001 and March, 2012. The study was approved by the
ethics committee of Shahid Sadoughi University of Med-
ical Sciences-Yazd. Inclusion criteria were adult patients
suffering from transitional cell bladder cancer and pa-
tients receiving chemotherapy or radiation treatment. Ex-
clusion criteria were patients under 18 years and patients
with non-transitional cell tumors. The underlying cause
of death was obtained from the death certificates and pa-
tients’ documents. The patients who died due to non-
cancer causes did not include the study. In order to gather
data, in the first step, patient information documents
were collected by referring to the cancer registry center of
Shahid Rahnemon and Shohada-Kargar Hospitals. In the
second step, the final status of the patients was checked
by phone calls. In case of unsuccessful phone calls, pa-
tients were re-contacted by telephone at least three times a
week. If the patients did not respond to the phone calls in a
two-week period, they were not included in the study. The
participants should be fully monitored to ensure their sur-
vival. Therefore, patients who were lost to follow up due to
migration or changed their phone numbers were excluded
from the study.
Data were collected by two questionnaires. The first
one contained general information of patients, including
demographic variables such as age, gender, stage of can-
cer, place of residence and type of treatment, which was
completed using the patient’s’ medical records. The sec-
ond questionnaire included the participants’ follow-up in-
formation such as, the contact time and the patients’ sta-
tus.
Data were analyzed using SPSS software version 17
(Chicago, IL, USA). Qualitative variables were reported
as proportions and continuous variables as mean ± SD.
Kaplan-Meier analysis was used to estimate survival in pa-
tients with bladder cancer. Log-rank test was performed to
compare the survival experience of two (or more) groups.
A Multivariate analysis was performed using the Cox pro-
portional hazard regression model. A P value less than 0.05
was considered statistically significant.
3. Results
In this study, 340 patients with bladder cancer were
followed up of whom 156 patients (45.9%) were alive and
184 cases (54.1%) had died due to cancer. Distribution of
patients with bladder cancer according to different vari-
ables is summarized in Table 1. Of all patients, 300 cases
(88.2%) were men, and 40 cases (11.8%) were male. The mean
age of total patients was 65.8 ± 13.6 years. Furthermore,
mean age for men and women was 64± 12.6 and 68± 14.4
years, respectively. The mean and median survival time
in patients were 68.55± 6.05 and 51 months, respectively.
In this study, men had a higher survival time mean than
women, but the difference was not significant (P = 0.33, Ta-
ble 1). Five-year bladder cancer survival rate was 51.4% for
all patients and was 51.5 and 50% for men and women, re-
spectively. The patients were divided into two age group,
30 - 69 and 70 - 89 year old. The highest number of pa-
tients was in the age group 30 - 69 year old (Table 1). Pa-
tients in age group 70 - 89 had significantly worse survival
rate than that age group 30 - 69 (P = 0.005, Table 1). In the
present study, the cancer survival time was estimated for
patients in different stages of bladder cancer. People suffer-
ing from bladder cancer stage 0 and 1 had the best survival
while the worst survival was seen in patients with bladder
cancer stage 4 (Table 1). Fifty nine cases were treated by
transurethral resection of bladder tumor (TURBT). These
patients had a longer survival period than those treated
by partial cystectomy or radical cystectomy. Data obtained
from comparing patients treated and untreated with ra-
diotherapy showed that radiation therapy decreased sur-
vival time in patients. Unlike intravesical chemotherapy,
systemic chemotherapy had a reducing effect on survival
time of patients (P = 0.0002). Results of multivariate sur-
vival analysis using Cox regression method are shown in
Table 2. This data revealed that age, cancer stage and type
of treatment play an important role in survival of bladder
cancer patients. Patients in age range of 30 - 69-year-old
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had the risk of bladder cancer 29.3 time more compared to
those between 70 and 89. The following parameters signif-
icantly increased HR for mortality risk of bladder cancer:
bladder cancer stage IV, partial cystectomy and radical cys-
tectomy. Systemic chemotherapy increased probability of
death in bladder cancer patients (HR: 0.28, Table 2).
4. Discussion
The present study was designed to evaluate, for the first
time, the survival rate in patients with bladder cancer in
Yazd, Iran. The data analyses showed that the overall sur-
vival rate at the end of one, three and five years were 91%,
58%, and 51.4%, respectively. In the study by Manterola et al.
conducted in Chile, the five-year survival rate for patients
with bladder cancer was reported as 50% (8). Sankara-
narayanan et al. estimated that the five-year survival rate
for bladder cancer in China, Republic of Korea, Turkey, Sin-
gapore was 63% - 76% (9). Another study reported that
the five-year survival rate of bladder cancer was 61, 66, 63,
59, and 52% in Caucasian, Japanese, Chinese, Filipino, and
Hawaiian patients, respectively (10). In the present study,
the survival rate of patients with bladder cancer in Yazd
city of Iran is lower than the mentioned areas. In the study
by Shamsnia and colleagues in Shiraz city, the bladder can-
cer survival rates were 94.40%, 68.38% and 49.30% at 1, 3,
and 5 years, respectively (7). In another report from Shi-
raz Hospitals, the survival accumulation at the end of 1, 3, 5
years were 89%, 71%, and 57% that are significantly higher
than survival of patients in Yazd city (4). Differences in
bladder cancer survival times can be due to differences in
socioeconomic conditions, proper screening, and the early
diagnosis of the disease using new methods.
In 2012, the number of bladder cancer death in Asia
was 524,465 cases. Mortality in men (67.1%) was more than
women (32.9%) (1). In the present study, the five-year sur-
vival rate in Yazdi male and female patients suffering from
bladder cancer was 51.5% and 50%, respectively, and no sig-
nificant difference was obtained in survival time between
male and female patients (P = 0.33). Compatible with our
data, Shamsnia and colleagues did not found a significant
difference between sexes of patients and bladder cancer in
Shiraz city (7). Also, Rezaianzadeh et al. did not observe any
significant difference in the survival rate of Iranian blad-
der cancer patients based on sex (4). In our study, men
and women had the mean survival time of 77.35 and 44.20
months, respectively, but this difference was not signifi-
cant. In contrast to our results, in some studies women had
significantly poorer bladder cancer survival than men (11,
12). A reason for such difference may be the small number
of female patients in our study.
The 5-year survival rate in Yazdi patients with blad-
der cancer showed a significant difference regarding aged
groups. The older patients (70 - 89 years vs. 30 - 69 years)
had lower survival. In another study reported that the sur-
vival rates of the patients in the age group of 60 - 70 and 70
- 80 years reduced respectively 1.3 and 1.2 times in compari-
son to those under 60 years old (13). Results of the present
study reveal that the age plays an important role in sur-
vival of patients (Cox regression method). Patients in age
range of 30 - 69 year had the risk of bladder cancer 29.3 time
more compared to those in the age group 70 - 89 years. In a
study conducted by Shamsnia, patients in the age group of
50 - 60 and 60 - 70 years old had the risk of bladder cancer
2.7 and 4.7 times more in comparison to the patients aging
under 50 years (7). Consistent with our findings, many re-
ports approved the association of age with survival in pa-
tients with bladder cancer (4, 6, 7, 14).
Results of the present study showed that type of cancer
treatment is an influential factor in survival of patients. Pa-
tients treated by TURBT method had better survival than
those who had undergone partial or radical cystectomy.
People who received the systemic chemotherapy had sig-
nificantly a lower survival time comparing to those who
were not treated with this method. In a study conducted
in Iran (4) and in the study by Gulliford et al. (13), type
of cancer therapy was indicated as a significant factor in
the survival of patients. Consistent with our findings, in
these studies, the chemotherapy was associated with de-
creased five-year survival and surgery method increased
survival time of bladder cancer patients. In the present
study, intravesical chemotherapy did not significantly re-
duced survival time, rather increased it. Several studies
have reported that intravesical chemotherapy decreased
cancer progression and improved survival (15). Literature
data revealed that the 5-year survival of patients suffering
from invasive bladder cancer under radiotherapy is 20% -
41% (16, 17). In our study, the 5-year survival of patients
treated by radiotherapy is 38% that is comparable to pre-
vious reported data.
In the present study, no significant difference was ob-
served in survival time of bladder cancer patients between
urban and rural residents. This showed that the health sta-
tuses of urban Yazdi residents was similar to those of ru-
ral counterparts. This data is not consistent with other re-
sults of cancer research in rural and urban areas world-
wide. Pang et al. reported a clear difference in the blad-
der cancer mortality rates in the urban and rural areas of
China (14). In India, cancer survival in rural areas is lower
than big cities (15). According to the cancer research find-
ings in Australia, villages had demonstrably the poorer sur-
vival when compared to major cities (18). The difference be-
tween our findings and above researches may be due to our
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Table 1. Survival Rates in Patients with Bladder Cancer According to Some Variables
Variables No. (%) Survival Rate, % Mean Survival Time± SE, Mo P Value
1 year 3 year 5 year
Gender 0.33
Male 300 (88.2) 92.5 61 51.5 70.35± 6.42
Female 40 (11.8) 91 59.5 50 44.20± 8.75
Total 340 (100) 91 58 51.4 68.55± 6.05
Age, y 0.005
30 - 69 192 (53.5) 91.5 55 42 80.78± 7.87
70 - 89 148 (43.5) 91 46 26 50.87± 7.60
place of residence
Urban 264 (77.6) 91.5 60 36 70.73± 6.84 0.55
Rural 76 (22.4) 90 55 22 48.72± 7.06
Stage 0.0003
0 + I 140 (41.2) 98 86 66 82.43± 9.19
II 84 (24.7) 88 42 40 46.23± 10.08
IV 40 (11.8) 100 20 0 26.10± 2.27
Unknown 76 (22.4) 97 85 78 85.75± 10.68
Treatment
TURBT 236 (69.4) 98 82 60 82.97± 7.42
0.0003Partial cystectomy 28 (8.2) 100 26 0 24.14± 4.78
Radical cystectomy 76 (22.4) 97 41 30 44.73± 8.79
Radiotherapy 56 (16.5) 0.058
Yes 100 38 38 39.25± 7.31
No 98 62 52 72.53± 6.64
Systemic chemotherapy 116 (34.1) 0.0002
Yes 98 42 30 40.84± 6.63
No 97 77 59 84.56± 7.56
Intravesical chemotherapy 180 (54.1) 0.49
Yes 98 62 54 72.04± 8.11
No 100 55 42 60.89± 7.83
Table 2. Results of Multivariate Survival Analysis Using Cox Regression Method
Variables Hazard Ratio Confidence Interval (95%) P Value
Age, y
70 - 89 1 - Ref
30 - 69 29.35 7.07 - 121.72 < 0.001
Stage
0 + I 1 - Ref
II 1.98 0.97 - 4.04 0.059
IV 2.93 1.28 - 6.72 0.011
Treatment
TURBT 1 - Ref
Partial cystectomy 3.59 1.53 - 8.40 0.003
Radical cystectomy 2.63 1.39 - 4.97 0.003
Systemic chemotherapy
Yes 1 - Ref
No 0.28 0.15 - 0.51 < 0.001
small sample size or an acceptable health care system in
our villages. Cancer survival data from metropolitan and
rural areas in Iran are low and further studies are neces-
sary.
In conclusion, the survival rate of patients with blad-
der cancer in this study was lower than other reports. Since
age and stage of bladder cancer are the most important fac-
tors in survival time, continuous screening of older peo-
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ple for cancer diagnosis in early stages seemed to improve
survival of patients. Intravesical chemotherapy can be the
best treatment option for increasing the survival of pa-
tients.
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